2. Anti-infection
  3. CMV HSV Orthopoxvirus
  4. Brincidofovir

Brincidofovir  (Synonyms: CMX001; HDP-CDV)

目录号: HY-14532 纯度: 99.00%
COA 产品使用指南

摩尔计算器

Brincidofovir (CMX001) 是 Cidofovir 的脂质结合前体药物，是一种口服、长效抗病毒药物。Brincidofovir 对广泛的 DNA 病毒具有活性，包括巨细胞病毒 (CMV)、腺病毒 (ADV)、水痘带状疱疹病毒、单纯疱疹病毒、多瘤病毒、乳头瘤病毒、痘病毒和混合双链 DNA 病毒感染。Brincidofovir是一种具有口服活性的抗病毒化合物，已被证明在体外和体内对正痘病毒有效。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Brincidofovir Chemical Structure

Brincidofovir Chemical Structure

CAS No. : 444805-28-1

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
1 mg ￥960
In-stock
5 mg ￥2240
In-stock
10 mg ￥3360
In-stock
25 mg 现货 询价
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Customer Review

Brincidofovir 相关抗体

Top Publications Citing Use of Products

查看 HSV 亚型特异性产品:

查看所有亚型
HSV-1 HSV-2 HSV

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo.[1][2][3][4].

IC50 & Target

EC50: 5.5 nM (anti-CMV, in PDA at 7 dpi)
细胞效力
(Cellular Effect)
Cell Line Type Value Description References
BSC-1 EC50
0.125 μM
Compound: 1, HDP-CDV
Antiviral activity against Ectromelia virus Moscow infected in african green monkey BSC1 cells after 4 to 5 days by plaque reduction assay
Antiviral activity against Ectromelia virus Moscow infected in african green monkey BSC1 cells after 4 to 5 days by plaque reduction assay
[PMID: 21493074]
BSC-1 CC50
25.3 μM
Compound: 1, HDP-CDV
Cytotoxicity against african green monkey BSC1 cells after 2 to 4 hrs by MTS assay
Cytotoxicity against african green monkey BSC1 cells after 2 to 4 hrs by MTS assay
[PMID: 21493074]
HFF EC50
0.08 μM
Compound: 1, HDP-CDV
Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells after 3 days by plaque reduction assay
Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells after 3 days by plaque reduction assay
[PMID: 21493074]
HFF EC50
0.13 μM
Compound: CMX001
Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction plaque formation after 3 days
Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction plaque formation after 3 days
[PMID: 17724153]
HFF EC50
0.14 μM
Compound: CMX001
Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction plaque formation after 3 days
Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction plaque formation after 3 days
[PMID: 17724153]
HFF EC50
0.2 μM
Compound: 1, HDP-CDV
Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells after 3 days by plaque reduction assay
Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells after 3 days by plaque reduction assay
[PMID: 21493074]
HFF EC50
0.24 μM
Compound: CMX001
Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction plaque formation after 3 days
Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction plaque formation after 3 days
[PMID: 17724153]
HFF EC50
0.6 μM
Compound: HDP-CDV
Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days
Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days
[PMID: 17846137]
HFF EC50
0.8 μM
Compound: HDP-CDV
Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days
Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days
[PMID: 17846137]
HFF EC50
1.1 μM
Compound: HDP-CDV
Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days
Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days
[PMID: 17846137]
HFF CC50
25 μM
Compound: 1, HDP-CDV
Cytotoxicity against human HFF cells assessed as reduction in cell viability after 7 days by neutral red uptake assay
Cytotoxicity against human HFF cells assessed as reduction in cell viability after 7 days by neutral red uptake assay
[PMID: 21493074]
HFF CC50
31 μM
Compound: HDP-CDV
Cytotoxicity against HFF cells after 7 days
Cytotoxicity against HFF cells after 7 days
[PMID: 17846137]
HFF CC50
42 μM
Compound: CMX001
Cytotoxicity against HFF cells after 7 days by neutral red assay
Cytotoxicity against HFF cells after 7 days by neutral red assay
[PMID: 17724153]
体内研究
(In Vivo)

Brincidofovir (BCV) (20 mg/kg；口服；在第 1、3、5、7、10、14、17、21 和 24 天) 延长 IHD-J-Luc VACV 处理的免疫缺陷 BALB/c nu/nu 小鼠的存活期[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nu/nu mice (infected with IHD-J-Luc VACV)[3]
Dosage: 20 mg/kg
Administration: P.o.; on days 1, 3, 5, 7, 10, 14, 17, 21, and 24
Result: On days 1, 3, and 5 maintained their weights initially but started to lose weight beginning on day 9 and succumbed between days 24 and 29 postchallenge.
Clinical Trial
分子量

561.69

Formula

C27H52N3O7P
CAS 号
性状

固体

颜色

White to off-white

运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
细胞实验： 

DMSO 中的溶解度 : 1 mg/mL (1.78 mM; adjust pH to 8 with NaOH and heat to 50°C; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.7803 mL 8.9017 mL 17.8034 mL
5 mM --- --- ---
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物溶解方案计算器
请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

只
由于实验过程有损耗，建议您多配一只动物的量
计算结果
工作液所需浓度 : mg/mL
纯度 & 产品资料
参考文献

Brincidofovir 相关分类

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.7803 mL 8.9017 mL 17.8034 mL 44.5085 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Brincidofovir444805-28-1CMX001 HDP-CDVCMX 001CMX-001CMVHSVOrthopoxvirusCytomegalovirusHerpes simplex viruslipid-conjugatedprodrugantiviralDNAvirusesinfectionInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Brincidofovir
目录号：
HY-14532
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z